{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T03:30:20Z","timestamp":1767065420710,"version":"3.44.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T00:00:00Z","timestamp":1739836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T00:00:00Z","timestamp":1739836800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Urol Nephrol"],"DOI":"10.1007\/s11255-025-04394-5","type":"journal-article","created":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T19:06:12Z","timestamp":1739905572000},"page":"2425-2433","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Varieties of altered TFE3 can occur in MiT-family-related renal cell carcinomas"],"prefix":"10.1007","volume":"57","author":[{"given":"Allison K.","family":"Kennedy","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hassan D.","family":"Kanaan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kanika","family":"Arora","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harry","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jason M.","family":"Hafron","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shelly L.","family":"Kaufman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark A.","family":"Micale","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ping L.","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,2,18]]},"reference":[{"issue":"1","key":"4394_CR1","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/s41420-023-01395-0","volume":"9","author":"X Li","year":"2023","unstructured":"Li X, Chen Y, Gong S, Chen H, Liu H, Li X, Hao J (2023) Emerging roles of TFE3 in metabolic regulation. Cell Death Discov 9(1):93","journal-title":"Cell Death Discov"},{"issue":"6","key":"4394_CR2","doi-asserted-by":"publisher","first-page":"e202102001","DOI":"10.1083\/jbc.202102001","volume":"220","author":"C Yang","year":"2021","unstructured":"Yang C, Wang X (2021) Lysosome biogenesis: regulation and functions. J Cell Biol 220(6):e202102001. https:\/\/doi.org\/10.1083\/jbc.202102001","journal-title":"J Cell Biol"},{"issue":"2","key":"4394_CR3","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1038\/modpathol.2011.169","volume":"25","author":"S Macher-Goeppinger","year":"2012","unstructured":"Macher-Goeppinger S, Roth W, Wagener N, Hohenfellner M, Penzel R, Haferkamp A, Schirmacher P, Aulmann S (2012) Molecular heterogeneity of TFE3 activation in renal cell carcinomas. Mod Pathol 25(2):308\u2013315","journal-title":"Mod Pathol"},{"issue":"5","key":"4394_CR4","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1177\/10668969221108517","volume":"31","author":"M Kmeid","year":"2023","unstructured":"Kmeid M, Akgul M (2023) TFE3 rearrangement and expression in renal cell carcinoma. Int J Surg Pathol 31(5):509\u2013520","journal-title":"Int J Surg Pathol"},{"issue":"3","key":"4394_CR5","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.21037\/tau-20-1150","volume":"10","author":"A Cimadamore","year":"2021","unstructured":"Cimadamore A, Cheng L, Scarpelli M, Massari F, Mollica V, Santoni M, Lopez-Beltran A, Montironi R, Moch H (2021) Towards a new WHO classification of renal cell tumor: what the clinician needs to know-a narrative review. Transl Androl Urol 10(3):1506\u20131520","journal-title":"Transl Androl Urol"},{"issue":"6","key":"4394_CR6","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1093\/ajcp\/aqad089","volume":"160","author":"XM Wang","year":"2023","unstructured":"Wang XM, Shao L, Xiao H, Myers JL, Pantanowitz L, Skala SL, Udager AM, Vaishampayan U, Mannan R, Dhanasekaran SM, Chinnaiyan AM, Betz BL, Brown N, Mehra R (2023) Lessons from 801 clinical TFE3\/TFEB fluorescence in situ hybridization assays performed on renal cell carcinoma suspicious for MiTF family aberrations. Am J Clin Pathol 160(6):549\u2013554","journal-title":"Am J Clin Pathol"},{"issue":"20","key":"4394_CR7","doi-asserted-by":"publisher","first-page":"5735","DOI":"10.1016\/j.cell.2024.07.038","volume":"187","author":"M Achom","year":"2024","unstructured":"Achom M, Sadagopan A, Bao C, McBride F, Li J, Konda P, Tourdot RW, Xu Q, Nakhoul M, Gallant DS, Ahmed UA, O\u2019Toole J, Freeman D, Lee GM, Hecht JL, Kauffman EC, Einstein DJ, Choueiri TK, Zhang CZ, Viswanathan SR (2024) A genetic basis for sex differences in Xp11 translocation renal cell carcinoma. Cell 187(20):5735-5752e25","journal-title":"Cell"},{"key":"4394_CR8","doi-asserted-by":"crossref","unstructured":"Li J, Huang K, F McBride, Sadagopan A, Gallant DS, Thakur M, Khanna P, Li B, Ge M, Weiss CN, Achom M, Xu Q, Huang K, Ryback BA, Gui M, Bar-Peled L, Viswanathan SR (2024) TFE3 fusions direct an oncogenic transcriptional program that drives OXPHOS and unveils vulnerabilities in translocation renal cell carcinoma. bioRxiv","DOI":"10.1101\/2024.08.09.607311"},{"issue":"8","key":"4394_CR9","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1038\/nrurol.2014.162","volume":"11","author":"EC Kauffman","year":"2014","unstructured":"Kauffman EC, Ricketts CJ, Rais-Bahrami S, Yang Y, Merino MJ, Bottaro DP, Srinivasan R, Linehan WM (2014) Molecular genetics and cellular features of TFE3 and TFEB fusion kidney cancers. Nat Rev Urol 11(8):465\u2013475","journal-title":"Nat Rev Urol"},{"issue":"14","key":"4394_CR10","doi-asserted-by":"publisher","first-page":"7649","DOI":"10.3390\/ijms23147649","volume":"23","author":"A Simonaggio","year":"2022","unstructured":"Simonaggio A, Ambrosetti D, Verkarre V, Auvray M, Oudard S, Vano YA (2022) MiTF\/TFE translocation renal cell carcinomas: from clinical entities to molecular insights. Int J Mol Sci 23(14):7649. https:\/\/doi.org\/10.3390\/ijms23147649","journal-title":"Int J Mol Sci"},{"issue":"3","key":"4394_CR11","first-page":"283","volume":"36","author":"F Lin","year":"2006","unstructured":"Lin F, Zhang PL, Yang XJ, Prichard JW, Lun M, Brown RE (2006) Morphoproteomic and molecular concomitants of an overexpressed and activated mTOR pathway in renal cell carcinomas. Ann Clin Lab Sci 36(3):283\u2013293","journal-title":"Ann Clin Lab Sci"},{"issue":"27","key":"4394_CR12","doi-asserted-by":"publisher","first-page":"41612","DOI":"10.18632\/oncotarget.9508","volume":"7","author":"RE Brown","year":"2016","unstructured":"Brown RE, Buryanek J, Tammisetti VS, McGuire MF, Csencsits-Smith K (2016) Morphoproteomics and biomedical analytics confirm the mTORC2\/Akt pathway as a resistance signature and activated ERK and STAT3 as concomitant prosurvival\/antiapoptotic pathways in metastatic renal cell carcinoma (RCC) progressing on rapalogs: pathogenesis and therapeutic options. Oncotarget 7(27):41612\u201341621","journal-title":"Oncotarget"},{"issue":"1","key":"4394_CR13","first-page":"3","volume":"53","author":"KJ Zhang","year":"2023","unstructured":"Zhang KJ, Qu Z, Pszenica E, Hafron JM, Zhang PL, Brown RE (2023) Review: mammalian target of rapamycin (mTOR) pathway is critical in developing most renal cell tumors. Ann Clin Lab Sci 53(1):3\u201313","journal-title":"Ann Clin Lab Sci"},{"issue":"2","key":"4394_CR14","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1007\/s11255-013-0522-z","volume":"46","author":"PL Zhang","year":"2014","unstructured":"Zhang PL, Mashni JW, Sabbisetti VS, Schworer CM, Wilson GD, Wolforth SC, Kernen KM, Seifman BD, Amin MB, Geddes TJ, Lin F, Bonventre JV, Hafron JM (2014) Urine kidney injury molecule-1: a potential non-invasive biomarker for patients with renal cell carcinoma. Int Urol Nephrol 46(2):379\u2013388","journal-title":"Int Urol Nephrol"},{"issue":"11","key":"4394_CR15","doi-asserted-by":"publisher","first-page":"1893","DOI":"10.1007\/s11255-019-02231-0","volume":"51","author":"KJ Zhang","year":"2019","unstructured":"Zhang KJ, Wilson GD, Kara S, Majeske A, Zhang PL, Hafron JM (2019) Diagnostic role of kidney injury molecule-1 in renal cell carcinoma. Int Urol Nephrol 51(11):1893\u20131902","journal-title":"Int Urol Nephrol"},{"issue":"22","key":"4394_CR16","doi-asserted-by":"publisher","first-page":"2271","DOI":"10.1056\/NEJMoa066838","volume":"356","author":"G Hudes","year":"2007","unstructured":"Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, Staroslawska E, Sosman J, McDermott D, Bodrogi I, Kovacevic Z, Lesovoy V, Schmidt-Wolf IG, Barbarash O, Gokmen E, O\u2019Toole T, Lustgarten S, Moore L, Motzer RJ, Global AT (2007) Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 356(22):2271\u20132281","journal-title":"N Engl J Med"},{"issue":"9637","key":"4394_CR17","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1016\/S0140-6736(08)61039-9","volume":"372","author":"RJ Motzer","year":"2008","unstructured":"Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, Grunwald V, Thompson JA, Figlin RA, Hollaender N, Urbanowitz G, Berg WJ, Kay A, Lebwohl D, Ravaud A, R.-S. Group (2008) Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 372(9637):449\u2013456","journal-title":"Lancet"},{"issue":"1","key":"4394_CR18","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1002\/1878-0261.13699","volume":"19","author":"A Hernandez-Prat","year":"2025","unstructured":"Hernandez-Prat A, Rodriguez-Vida A, Cardona L, Qin M, Arpi-Llucia O, Soria-Jimenez L, Menendez S, Quimis FG, Galindo M, Arriola E, Salido M, Juanpere-Rodero N, Rojo F, Muntasell A, Albanell J, Rovira A, Bellmunt J (2025) Enhancing immunotherapy through PD-L1 upregulation: the promising combination of anti-PD-L1 plus mTOR inhibitors. Mol Oncol 19(1):151\u2013172","journal-title":"Mol Oncol"},{"issue":"2","key":"4394_CR19","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1097\/01.pas.0000185382.80844.b1","volume":"30","author":"SK Tickoo","year":"2006","unstructured":"Tickoo SK, de Peralta-Venturina MN, Harik LR, Worcester HD, Salama ME, Young AN, Moch H, Amin MB (2006) Spectrum of epithelial neoplasms in end-stage renal disease: an experience from 66 tumor-bearing kidneys with emphasis on histologic patterns distinct from those in sporadic adult renal neoplasia. Am J Surg Pathol. 30(2):141\u2013153","journal-title":"Am J Surg Pathol."},{"issue":"1","key":"4394_CR20","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1177\/1066896911414273","volume":"20","author":"R Bhatnagar","year":"2012","unstructured":"Bhatnagar R, Alexiev BA (2012) Renal-cell carcinomas in end-stage kidneys: a clinicopathological study with emphasis on clear-cell papillary renal-cell carcinoma and acquired cystic kidney disease-associated carcinoma. Int J Surg Pathol 20(1):19\u201328","journal-title":"Int J Surg Pathol"},{"issue":"3","key":"4394_CR21","doi-asserted-by":"publisher","first-page":"657","DOI":"10.3390\/biomedicines10030657","volume":"10","author":"ZM El-Zaatari","year":"2022","unstructured":"El-Zaatari ZM, Truong LD (2022) Renal cell carcinoma in end-stage renal disease: a review and update. Biomedicines 10(3):657. https:\/\/doi.org\/10.3390\/biomedicines10030657","journal-title":"Biomedicines"},{"issue":"3","key":"4394_CR22","first-page":"371","volume":"54","author":"Y Al-Othman","year":"2024","unstructured":"Al-Othman Y, Daraiseh SI, Schwartz JD, Kroneman O, Putchakayala K, Elzieny M, Thorburn CA, Cohn SR, Kanaan HD, Bedi DS, Lamb CA, Qu ZH, Hafron JM, Zhang PL (2024) Malignant tumors identified in adult polycystic kidney disease can be derived from both proximal tubular and distal tubular origins. Ann Clin Lab Sci 54(3):371\u2013377","journal-title":"Ann Clin Lab Sci"},{"issue":"7","key":"4394_CR23","doi-asserted-by":"publisher","first-page":"1392","DOI":"10.1038\/s41379-021-00779-w","volume":"34","author":"K Trpkov","year":"2021","unstructured":"Trpkov K, Hes O, Williamson SR, Adeniran AJ, Agaimy A, Alaghehbandan R, Amin MB, Argani P, Chen YB, Cheng L, Epstein JI, Cheville JC, Comperat E, da Cunha IW, Gordetsky JB, Gupta S, He H, Hirsch MS, Humphrey PA, Kapur P, Kojima F, Lopez JI, Maclean F, Magi-Galluzzi C, McKenney JK, Mehra R, Menon S, Netto GJ, Przybycin CG, Rao P, Rao Q, Reuter VE, Saleeb RM, Shah RB, Smith SC, Tickoo S, Tretiakova MS, True L, Verkarre V, Wobker SE, Zhou M, Gill AJ (2021) New developments in existing WHO entities and evolving molecular concepts: the genitourinary pathology society (GUPS) update on renal neoplasia. Mod Pathol 34(7):1392\u20131424","journal-title":"Mod Pathol"}],"container-title":["International Urology and Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-025-04394-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11255-025-04394-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-025-04394-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T05:58:38Z","timestamp":1757138318000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11255-025-04394-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,18]]},"references-count":23,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2025,8]]}},"alternative-id":["4394"],"URL":"https:\/\/doi.org\/10.1007\/s11255-025-04394-5","relation":{},"ISSN":["1573-2584"],"issn-type":[{"type":"electronic","value":"1573-2584"}],"subject":[],"published":{"date-parts":[[2025,2,18]]},"assertion":[{"value":"8 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}